Genmab A/S (GMAB) Expands Tivdak and Epkinly Commercial Push Globally

We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Genmab A/S is one of them.

Genmab A/S (NASDAQ:GMAB), based in Copenhagen, is a biotechnology company focused on developing antibody-based therapies for cancer and other serious diseases. It is among the cheap biotech stocks to buy. With over 45 INDs since 1999 and a pipeline of around 10 programs, the company has contributed to the approval of eight medicines and co-owns products such as Tivdak and Epkinly/Tepkinly, collaborating with major pharma players including Pfizer and AbbVie.

In Q2 2025, Genmab A/S (NASDAQ:GMAB) reported 19% year-over-year revenue growth and a 56% increase in operating profit which was driven by royalties from DARZALEX and Kasimpta, and strong sales of McKinley and Tivdak. The corporation ended H1 2025 with approximately $3 billion in cash, supporting ongoing R&D and growth initiatives. The business also completed a share buyback in June, reflecting confidence in its growth and commitment to shareholders.

Strategically, the firm is accelerating its late-stage pipeline, including the Phase 3 EPCORE FL-1 trial, which met dual primary endpoints in relapsed/refractory follicular lymphoma. The company is intensifying commercial efforts for Epkinly and Tivdak globally and recently increased share capital through employee warrant exercises, signaling continued investment in talent and innovation.

Looking ahead, Genmab A/S (NASDAQ:GMAB) aims to become a fully integrated biotech powerhouse by 2030, leveraging its KYSO antibody platform to deliver transformative therapies. Partnerships with large pharmaceutical companies remain central to strengthening its R&D capabilities and global commercialization reach.

While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.